Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with ...

A new drug delivery system shows promise for treating a rare, aggressive form of cancer affecting pregnant women and new mothers, and it has potential with other cancers as well.

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...

A new report explores the disproportionately high death rate among Black women in the Delta from cervical cancer.

A new research paper was published in Oncoscience's Volume 12 on January 20, 2025, titled "Maternal, delivery and neonatal outcomes in women with cervical cancer. A study of a population database." ...

Here are 5 important questions to ask if you’ve been told you have cervical dysplasia: ...

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

A new research paper was published in Oncoscience’s Volume 12 on January 20, 2025, titled “Maternal, delivery and neonatal ...

Charleston County Master Deputy Jessica Coston describes how she beat back cervical cancer after her symptoms were initially ...

Regeneron stock jumped Tuesday after the biotech giant topped Wall Street's December-quarter calls on the back of its cancer drug Libtayo.

Northwell Health partnered with Stacker to explore how a new Pap smear alternative may help prevent deaths from cervical ...

Cervical cancer is usually caused by HPV infection. Exposure to multiple sexual partners, especially without using a condom, increases the risk of HPV. In utero diethylstilbestrol (DES) exposure ...